Laetitia Dahan

5PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 14, 2025
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.

Camille Evrard, Antoine Pelras, Simon Rivet

|Sep 05, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Emeric Boisteau, Laetitia Dahan, Nicolas Williet

|Mar 15, 2022
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.

Clémence Canton, Olayidé Boussari, Mathieu Boulin

|Oct 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Jean Marc Phelip, Jérôme Desrame, Julien Edeline

|Jul 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.

Laetitia Dahan, Nicolas Williet, Karine Le Malicot

Pageof 1

Frequent Collaborators

3 joint publications

Karine Le Malicot

3 joint publications

Jean-Baptiste Bachet

2 joint publications

Jean-Marc Phelip

2 joint publications

David Malka